Deva Holding A.S.
| Company type | Pharmaceutical Company |
|---|---|
| BİST: DEVA | |
| Industry | Pharmaceuticals |
| Founded | September 22, 1958 |
| Headquarters | Istanbul, Turkey |
Key people | Mr. Philipp Haas (Chairman and CEO) |
| Products | pharmaceuticals |
| Revenue | US$423 million (2024) |
| US$76 million (2024) | |
| US$1.5 million (2024) | |
| Total assets | US$855 million (2024) |
| Total equity | US$638 million (2024) |
Number of employees | 3.000 |
| Website | www.deva.com.tr |
DEVA Holding A.Ş. is a leading Turkish pharmaceutical company founded in 1958. As of 2024, it ranked 3rd in unit sales (5.3%) and 6th in TL sales (2.9%) in Turkey’s pharmaceutical market.
The company operates three EU GMP- and US FDA-approved facilities in Çerkezköy and Kartepe, with an annual production capacity of 620 million units. DEVA’s portfolio covers 10 therapeutic areas, including cardiovascular, dermatology, ophthalmology, hematology, and anti-infectives, and includes 1,404 registered products across 82 countries.
Recognized as Turkey’s top pharmaceutical company in R&D spending by Turkishtime’s 2024 R&D 250 Report, DEVA employs over 500 researchers and 3,000 staff in total. Guided by sustainability and innovation, the company focuses on developing accessible, effective, and environmentally responsible healthcare solutions for both domestic and global markets.
Background
Founded in 1958, DEVA Holding A.Ş. has grown from a local manufacturer into one of Turkey’s largest producers of generic pharmaceuticals. Initially focused on essential medicines for the domestic market, the company steadily expanded through investments in technology, research, and compliance with international quality standards. Over time, it built a diverse product range and gained recognition for its reliability and affordability in healthcare.
By the 2000s, DEVA had transformed into a globally oriented company, obtaining EU GMP and US FDA certifications and entering numerous export markets. Today, it continues to strengthen its position through a broad generic portfolio, global distribution network, and consistent focus on R&D-driven growth and sustainability..[4][5]
References
- ^ "Antibiotic Long Distance Run". Fortune Magazine. 19 July 2019. Archived from the original on 2019-09-05. Retrieved 15 September 2019.
- ^ "5 Minutes Interview with: Philipp Haas - Deva". Pharma Horizon Magazine. 4 May 2017. Archived from the original on 2019-10-28. Retrieved 15 September 2019.
- ^ "Philipp Haas – Chairman & CEO, DEVA, Turkey". Pharma Boardroom Magazine. 29 November 2018. Archived from the original on 2019-10-28. Retrieved 15 September 2019.
- ^ "» 5 minutes interview with: Philipp Haas – DEVA". TKS Publisher. Retrieved 2019-10-28.
- ^ "DEVA.IS - Deva Holding AS Profile | Reuters". www.reuters.com. Retrieved 2019-10-28.
External links